Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST Clinic.

Purpose Wild-type gastrointestinal stromal tumors (WT-GISTs) that lack KIT or PDGFRA mutations represent a unique subtype of GIST that predominantly affects children. We sought to determine the effect on event-free survival (EFS) of staging variables, extent of resection, and repeat resection of tumors. Methods In 2008, a WT-GIST clinic was established at the National Cancer Institute, allowing the development of a large clinical database. We included participants who underwent resection of WT-GIST. Associations with EFS (ie, freedom from disease progression or recurrence) were evaluated using the Kaplan-Meier method and Cox proportional hazards modeling. Results Among 76 participants with WT-GISTs, the median follow-up was 4.1 years. Overall EFS (± SE) was 72.6 ± 5.4% at 1 year, 57.6 ± 6.2% at 2 years, 23.7 ± 6.0% at 5 years, and 16.3 ± 5.5% at 10 years postoperatively. Hazard of disease progression or recurrence was significantly increased for patients with metastatic disease (adjusted hazard ratio [AHR], 2.3; 95% CI, 1.0 to 5.1; P = .04) and > 5 mitoses per 50 high-power fields (AHR, 2.5; 95% CI, 1.1 to 6.0; P = .03), whereas there was no significant effect of negative microscopic resection margins (AHR, 0.9; 95% CI, 0.4 to 2.2; P = 0.86). There was no association between type of gastric resection (ie, anatomic v partial/wedge) and EFS ( P = .67). Repeated resection after the initial resection was significantly associated with decreasing postoperative EFS ( P < .01). Five patients (6%) died after initial enrollment in 2008. Conclusion WT-GIST is an indolent disease, and most patients survive with disease progression. We found no improvement in EFS with more extensive or serial resections. Disease progression or recurrence may be more closely related to tumor biology than surgical management. These data suggest that resections for WT-GISTs be restricted to the initial procedure and that subsequent resections be performed only to address symptoms such as obstruction or bleeding.

[1]  A. D. Van den Abbeele,et al.  Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  P. Meltzer,et al.  Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. , 2016, JAMA oncology.

[3]  C. Antonescu,et al.  Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence. , 2012, Journal of the American College of Surgeons.

[4]  C. Weldon,et al.  Pediatric gastrointestinal stromal tumor. , 2012, Seminars in pediatric surgery.

[5]  C. Antonescu,et al.  Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations , 2010, Proceedings of the National Academy of Sciences.

[6]  A. Pappo,et al.  Pediatric and wild-type gastrointestinal stromal tumor: new therapeutic approaches , 2010, Current opinion in oncology.

[7]  A. Agaimy Gastrointestinal stromal tumors (GIST) from risk stratification systems to the new TNM proposal: more questions than answers? A review emphasizing the need for a standardized GIST reporting. , 2010, International journal of clinical and experimental pathology.

[8]  C. Antonescu,et al.  NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[9]  J. Lasota,et al.  Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. , 2009, Archives of pathology & laboratory medicine.

[10]  A. Pappo,et al.  Pediatric gastrointestinal stromal tumors. , 2009, Hematology/oncology clinics of North America.

[11]  K. Owzar,et al.  Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  D. Mattison,et al.  Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatric Formulation Initiative: selected reports from working groups. , 2008, Clinical therapeutics.

[13]  Narasimhan P. Agaram,et al.  Novel V600E BRAF mutations in imatinib‐naive and imatinib‐resistant gastrointestinal stromal tumors , 2008, Genes, chromosomes & cancer.

[14]  C. Antonescu,et al.  Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST) , 2008, Cancer.

[15]  J. Fletcher,et al.  Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. , 2007, Cancer research.

[16]  A. D. Van den Abbeele,et al.  NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

[17]  T. Nishida,et al.  Surgical strategy for gastric gastrointestinal stromal tumors: laparoscopic vs. open resection , 2007, Surgical Endoscopy.

[18]  C. Antonescu,et al.  Results of Tyrosine Kinase Inhibitor Therapy Followed by Surgical Resection for Metastatic Gastrointestinal Stromal Tumor , 2007, Annals of surgery.

[19]  L. Sobin,et al.  Gastrointestinal Stromal Tumors of the Stomach in Children and Young Adults: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 44 Cases With Long-Term Follow-Up and Review of the Literature , 2005, The American journal of surgical pathology.

[20]  N. Socci,et al.  Gastrointestinal Stromal Tumors in Children and Young Adults: A Clinicopathologic, Molecular, and Genomic Study of 15 Cases and Review of the Literature , 2005, Journal of pediatric hematology/oncology.

[21]  B. Nilsson,et al.  Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era , 2005, Cancer.

[22]  J. Fletcher,et al.  Biology of gastrointestinal stromal tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  B. Gunawan,et al.  Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours , 2003, The British journal of surgery.

[24]  Samuel Singer,et al.  PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.

[25]  L. Sobin,et al.  Diagnosis of gastrointestinal stromal tumors: A consensus approach. , 2002, Human pathology.

[26]  B. Yeap,et al.  The effect of surgery and grade on outcome of gastrointestinal stromal tumors. , 2001, Archives of surgery.

[27]  L. Kindblom,et al.  Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. , 1998, The American journal of pathology.

[28]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[29]  R. DeMatteo,et al.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. , 2000, Annals of surgery.

[30]  Rascon [The National Cancer Institute]. , 1953, Boletin cultural e informativo - Consejo General de Colegios Medicos de Espana.